Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

CYP2C9 allelic variants and frequencies in a pediatric sickle cell disease cohort: implications for NSAIDs pharmacotherapy.

Clinical and translational science - 1 Oct 2014

Jaja Cheedy, Patel Niren, Scott Stuart A, Gibson Robert, Kutlar Abdullah

Abstract excerpt

Nonsteroidal anti-inflammatory drugs (NSAIDs) used to treat pain in patients with sickle cell disease (SCD) are metabolized by the CYP2C9 enzyme. Racial differences in CYP2C9 allele frequencies impact NSAIDs efficacy and safety. We determined the frequencies of CYP2C9 alleles in an African American pediatric SCD cohort. Genomic DNA was isolated from blood samples of 30 patients aged between 7 and 17 years....

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Adolescent
Share to Anemia, Sickle Cell

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Anti-Inflammatory Agents, Non-Steroidal

Share to Cohort Studies

Share to Cytochrome P-450 CYP2C9

Share to Demography

Share to Gene Frequency

Source

Open in PubMed Open full text

Identifiers

PMID: 24889181
DOI: 10.1111/cts.12172
PMCID: PMC4213284

Genes

CYP2C9
SCD

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 3 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

CYP2C9 allelic variants and frequencies in a pediatric sickle cell disease cohort: implications for NSAIDs pharmacotherapy.PMID 24889181Read ↗

Preemptive Genotyping of CYP2C8 and CYP2C9 Allelic Variants Involved in NSAIDs Metabolism for Sickle Cell Disease Pain Management.Semantic proximity Read ↗

Clinical Pharmacogenetics Implementation Consortium Guideline (CPIC) for CYP2C9 and Nonsteroidal Anti-Inflammatory Drugs.Semantic proximity Read ↗

Cytochrome P450 2D6 polymorphisms and predicted opioid metabolism in African American children with sickle cell disease.Semantic proximity Read ↗

Progressing Preemptive Genotyping of CYP2C19 Allelic Variants for Sickle Cell Disease Patients.Semantic proximity Read ↗

Pharmacogenetic Testing for Analgesic Adverse Effects: Pediatric Case Series.Semantic proximity Read ↗

Cytochrome P450 CYP2C19 genotypes in Nigerian sickle-cell disease patients and normal controls.Semantic proximity Read ↗

Pharmacogenetics for Safe Codeine Use in Sickle Cell Disease.Semantic proximity Read ↗

Clinical relevance of genetic polymorphisms in the human CYP2C subfamily.Semantic proximity Read ↗

Oral anticoagulation with warfarin is significantly influenced by steroids and CYP2C9 polymorphisms in children with cancer.Semantic proximity Read ↗

CYP2D6 Pharmacogenetics in Nigerian Sickle Cell Disease: Phase 1 of Implementing Pharmacogenomics Testing for Effective Care and Treatment in Africa (iPROTECTA) programSemantic proximity Read ↗

Pharmacogenetics to Predict Adverse Events Associated With Antidepressants.Semantic proximity Read ↗

Pharmacogenomics of Anti-Inflammatory Therapy: Toward Personalized Use of Nonsteroidal Anti-Inflammatory Drugs, Corticosteroids, and BiologicsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.